Supply and demand for hemophilia treatments—Systems-based approaches to mitigate the risk
Authors:
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 57 (6) , 731-734
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia ANew England Journal of Medicine, 2016
- Penny wise, pound foolish: an assessment of Canadian Hemophilia/inherited bleeding disorder comprehensive care program services and resourcesHaemophilia, 2016
- Survey of coagulation factor concentrates tender and procurement procedures in 38 European CountriesHaemophilia, 2015
- Purchasing factor concentrates in the 21st century through competitive tenderingHaemophilia, 2013
- Factor VIII Products and Inhibitor Development in Severe Hemophilia ANew England Journal of Medicine, 2013
- What Is Value in Health Care?New England Journal of Medicine, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia communityHaemophilia, 2003
- Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatmentHaemophilia, 1999
- Financial aspects of haemophilia care in Puerto Rico and other Latin American countriesHaemophilia, 1999